Montgomery Breast Center First to Install Breast Cancer Lesion-Localization System
MONTGOMERY, Ala., April 20 The Montgomery Breast Center of Montgomery, Ala., is the first center in the country to install and use the GammaLoc® lesion-localization system. This system is the only FDA-cleared device that enables gamma-guided, minimally invasive needle biopsy of suspicious lesions identified with Breast-Specific Gamma Imaging (BSGI). BSGI is performed by the Dilon 6800®, a gamma camera that is optimized to reveal lesions independent of tissue density and discover early stage cancers that are oftentimes not identified with other imaging methods, such as mammography, ultrasound and magnetic resonance imaging (MRI).
GammaLoc® helps the physician calculate the specific depth and location of the suspect lesion. A computer user interface with detailed step-by-step instructions guides the physician through the biopsy procedure. The GammaLoc® system utilizes a CorreLocator(TM) paddle and a StereoView(TM) imaging collimator system - a technique similar to that used in stereotactic X-ray localization.
Dr. Cynthia Lorino, Director of Breast Imaging at Montgomery Breast Center, has already performed successful biopsies with the GammaLoc® system. "This device allows for precise and efficient biopsies," she said. "BSGI often discovers cancerous lesions that are not seen on mammograms or ultrasound. Now we have a way to quickly sample this suspicious tissue and give accurate results for patient peace of mind."
The entire GammaLoc® system is small and portable, allowing physicians to perform molecular imaging-guided biopsy procedures anywhere on site. The compact design allows for 180-degree access during breast biopsies with optimal patient comfort.
"GammaLoc® is a significant tool for us to more effectively locate breast cancer and determine the best course of treatment," said Dr. Lorino.
As a follow-up to mammography, BSGI utilizes the Dilon 6800® Gamma Camera to help physicians see the breast more clearly and differentiate benign from malignant tissue. To perform BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal, healthy cells and generally appear as dark spots on the BSGI image.
About Dilon Diagnostics
Dilon Diagnostics, a brand of Dilon Technologies Inc., is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Technologies please visit www.dilon.com.
SOURCE Dilon Diagnostics, Inc.
You May Also Like